Forte Biosciences, Inc.
NasdaqCM · USDForte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Analytick AI is a research platform. Output is informational and not financial advice — trade at your own risk.
Analytick AI is a product of Analytick Inc. · Rockville, Maryland, 20852, United States
© 2026 Analytick AI
Be the first to share your outlook and start the conversation with other investors in the FBRX community.